Turkish Journal of Gastroenterology
Original Article

Trimetazidine has Promising Preventive Effects on Experimental Chronic Pancreatitis Rat Model

1.

Department of Gastroenterology, University of Health Sciences, Sultan Abdülhamid Han Hospital, İstanbul, Turkey

2.

Department of Internal Medicine, University of Health Sciences, Sultan Abdülhamid Han Hospital, İstanbul, Turkey

3.

Department of Pathology, University of Health Sciences, Sultan Abdülhamid Han Hospital, İstanbul, Turkey

Turk J Gastroenterol 2022; 33: 356-361
DOI: 10.5152/tjg.2022.211153
Read: 131 Downloads: 36 Published: 17 February 2022

Background: It was aimed to evaluate the preventive efficacy of trimetazidine in an experimental chronic pancreatitis rat model.

Methods: Chronic pancreatitis model was accomplished with caerulein and alcohol administration. In the study, 40 female Sprague Dawley rats were randomized into 5 groups containing 8 animals in each. Group 1 (chronic pancreatitis); group 2 (chronic pancreati- tis+low-dose trimetazidine group); group 3 (chronic pancreatitis+high-dose trimetazidine group); group 4 (placebo group (chronic pancreatitis + saline)); group 5 (sham group). 24 hours after the last injection, all animals were sacrificed. Tumor necrosis factor-alpha, transforming growth factor-β, malondialdehyde, and glutathione peroxidase levels were tested in blood samples. Histopathologic exam- inations were conducted by a senior pathologist who was unaware of the group allocations.

Results: Results of biochemical parameters of the trimetazidine groups (groups 2 and 3) were significantly favorable compared with the chronic pancreatitis group (group 1) (P < .05). The difference between the low-dose- and the high-dose trimetazidine group (group 3) was significant in terms of blood tests (P < .05). The difference between the low-dose trimetazidine group and the chronic pancreatitis group was not significant in terms of histopathologic scores (P > .05); however, the difference was significant between the high-dose trimetazidine group and the chronic pancreatitis group (P < .05).

Conclusions: To the best of our knowledge, this current research is the first study that evaluates trimetazidine’s efficacy in the chronic pancreatitis rat model. Trimetazidine has affirmative preventive properties in the chronic pancreatitis course.

Cite this article as: Kaplan M, Karakaya A, Tanoğlu A, et al. Trimetazidine has promising preventive effects on experimental chronic pancreatitis rat model. Turk J Gastroenterol. 2022;33(4):356-361.

Files
EISSN 2148-5607